Cubist says urinary tract infection drug succeeds in study

Cubist Pharmaceuticals Inc said its experimental treatment for a type of urinary tract infection showed it was as effective as an approved antibiotic.

The main goal of a late-stage trial was to show whether the treatment, a combination of ceftolozane and tazobactam, eradicated the infection and cured patients five to nine days after the last dose.

The most commonly reported adverse events of the treatment were headaches, constipation, hypertension, nausea and diarrhea.

Cubist said it was concluding another late-stage study with the drug in patients with complicated intra-abdominal infections, and expects to report results in late December.

Shares of the Massachusetts-based company closed at $65.50 on the Nasdaq on Friday.

(Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)

###

(Reuters)

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

New biomarkers may influence drug design and alternative treatments of cancer, study shows   UGA ecologist finds another cause of antibiotic resistance   New drug for neuroblastoma shows promise in phase I study   Baclofen shows promise in patients with alcohol-induced liver disease   Findings point to an ‘off switch’ for drug resistance in cancer   Stopping statins may benefit terminally ill patients   Cholesterol drug users may use pills as a license to overeat   Pfizer lung cancer drug beats chemo for previously untreated patients   Mass. General study identifies path to safer drugs for heart disease, cancer   Gates Foundation awards Notre Dame $23 million for malaria, dengue studies   Cancer drug protects against diabetes   Malaria drug target raises hopes for new treatments